Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
Recruiting · Phase 1, Phase 2 · NCT03564340
Conditions: Recurrent Ovarian Cancer, Recurrent Fallopian Tube Cancer, Recurrent Primary Peritoneal Cancer, Recurrent Endometrial Cancer, Endometrial Cancer, Low-grade Serous Ovarian Cancer
At a glance
- Research payments reported, 2025
- $2.9M
- U.S. investigators named
- 11
- Sites paid
- 9
- Planned or actual enrollment
- 890
About the trial
- Sponsor
- Regeneron Pharmaceuticals
- Tested
- Ubamatamab (drug), Cemiplimab (drug), Sarilumab (drug), Tocilizumab (drug)
- Dates
- Started 2018-05-21; completion 2027-05-10
- Results posted
- Not yet
The main purpose of this study is to: * Learn about the safety of ubamatamab and to find out what dose of ubamatamab can be given alone or with cemiplimab to patients with ovarian cancer or cancer of the uterus * The study will also look at the levels of ubamatamab and/or cemiplimab in the body and measure how well the body can remove the study drug(s). This is called pharmacokinetics * The study will also look at any signs that ubamatamab alone or with cemiplimab can treat recurrent advanced ovarian cancer or cancer of the uterus * To find out how safe and tolerable pretreatment is in combination with ubamatamab and to see how well it works to prevent or minimize Cytokine Release Syndrom…
From ClinicalTrials.gov, last updated 2026-09-25. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Regeneron Pharmaceuticals, Inc. reported $2.9M in research payments for this study in 2025 (137 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Rebecca Arend, M.D. Gynecologic Oncology · Birmingham, AL
- Chelsea V. Salyer, M.D. Gynecologic Oncology · Boise, ID
- Sara Bouberhan, MD Hematology & Oncology · Boston, MA
- Joyce F. Liu, MD Internal Medicine · Charlestown, MA
- Matthew S. Block, MD, PHD Medical Oncology · Rochester, MN
- June Y. Hou, M.D. Gynecologic Oncology · Bronx, NY
- Roisin E. O'cearbhaill, MB BCH Medical Oncology · New York, NY
- David M. O'malley, M.D. Gynecologic Oncology · Hilliard, OH
- Kathleen N. Moore, MD OB-GYN (Obstetrics & Gynecology) · Oklahoma City, OK
- Victor Moreno, MD General Practice · Maunabo, PR
- Erika P. Hamilton, M.D. Hematology & Oncology · Nashville, TN
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Memorial Sloan Kettering Cancer Center $1.5M
- University of Alabama Hospital, AL $754,563
- Dana Farber Mass General Brigham Cancer Care Inc $291,793
- South Texas Accelerated Research Therapeutics LLC $225,633
- The Ohio State University $60,301
- Sarah Cannon Research Institute LLC $51,029
- Virginia Commonwealth University $36,030
- $29,775
- The Trustees of Columbia University in The City of New York $25,902
- Mayo Clinic $10,900
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.